Payment overview · 2025
General Payments
$1,750.37
74 reported records · 21 companies
Healthcare provider profile · identity verified
David E Kim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARTERSVILLE, GA · NPI 1508959750
Verified facts
What the public records show
CMS Open Payments records show David E Kim, MD received $1,750.37 in general payments during 2025 across 74 reported records.
Novo Nordisk Inc accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $323.11 | 18.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.05 | 12.7% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $191.74 | 10.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.80 | 8.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.74 | 8.0% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $128.16 | 7.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.42 | 5.2% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $76.86 | 4.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.99 | 3.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.60 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.88 | 3.2% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $37.63 | 2.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.44 | 1.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.54 | 1.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.86 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.20 | 1.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.77 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.87 | 1.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.29 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.93 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,750.37 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $263.79 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $191.74 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $175.44 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $128.16 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.44 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.33 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.42 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.42 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.21 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $76.86 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.99 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.99 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.60 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.15 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.88 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.26 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.41 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.41 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.41 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.07 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 48 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
51 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 837 | 216 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 116 |
| Gabapentin | Gabapentin | 274 | 77 |
| Metformin Hcl | Metformin Hcl | 260 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 257 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 75 |
| Losartan Potassium | Losartan Potassium | 230 | 69 |
| Meloxicam | Meloxicam | 230 | 91 |
| Lisinopril | Lisinopril | 217 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 64 |
| Alprazolam | Alprazolam | 191 | 40 |
| Tramadol Hcl | Tramadol Hcl | 189 | 48 |
| Furosemide | Furosemide | 185 | 62 |
| Ozempic | Semaglutide | 181 | 37 |
| Ezetimibe | Ezetimibe | 178 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 47 |
| Montelukast Sodium | Montelukast Sodium | 157 | 45 |
| Potassium Chloride | Potassium Chloride | 139 | 36 |
| Fluconazole | Fluconazole | 138 | 46 |
| Liothyronine Sodium | Liothyronine Sodium | 137 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 134 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 43 |
| Atenolol | Atenolol | 129 | 31 |
| Lorazepam | Lorazepam | 129 | 37 |
| Prednisone | Prednisone | 127 | 56 |
| Metformin Hcl Er | Metformin Hcl | 122 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 36 |
| Jardiance | Empagliflozin | 111 | 26 |
| Clonazepam | Clonazepam | 110 | 34 |
| Omeprazole | Omeprazole | 104 | 32 |
| Synthroid | Levothyroxine Sodium | 102 | 28 |
| Glipizide | Glipizide | 101 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 99 | 17 |
| Alendronate Sodium | Alendronate Sodium | 98 | 31 |
| Mounjaro | Tirzepatide | 98 | 16 |
| Famotidine | Famotidine | 96 | 32 |
| Fenofibrate | Fenofibrate | 91 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 17 |
| Allopurinol | Allopurinol | 80 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 24 |
| Pregabalin | Pregabalin | 78 | 25 |
| Trazodone Hcl | Trazodone Hcl | 78 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 19 |
| Glimepiride | Glimepiride | 61 | 22 |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Memantine Hcl | Memantine Hcl | 60 | 19 |
| Simvastatin | Simvastatin | 59 | 21 |
| Buspirone Hcl | Buspirone Hcl | 57 | 21 |
| Levofloxacin | Levofloxacin | 57 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Donepezil Hcl | Donepezil Hcl | 54 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 13 |
| Verapamil Hcl | Verapamil Hcl | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 51 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 39 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 12 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Ibuprofen | Ibuprofen | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 26 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 20 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 39 |
| Carvedilol | Carvedilol | 41 | 14 |
| Temazepam | Temazepam | 41 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Finasteride | Finasteride | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Estradiol | Estradiol | 35 | 11 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 34 | 13 |
| Eliquis | Apixaban | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 14 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 13 |
| Digoxin | Digoxin | 33 | suppressed |
| Indapamide | Indapamide | 33 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Primidone | Primidone | 31 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Triazolam | Triazolam | 28 | suppressed |
| Cefdinir | Cefdinir | 26 | 22 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 18 |
| Mupirocin | Mupirocin | 26 | 21 |
| Nitroglycerin | Nitroglycerin | 26 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 16 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nateglinide | Nateglinide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Isradipine | Isradipine | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Perphenazine | Perphenazine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,750.37 · 74 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, UBRELVY, UNITHROID, VRAYLAR, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error